The 67th World Leprosy Day — January 26, 2020

World Leprosy Day was proposed by French humanitarian Raoul Follereau in 1954 (1) and has been annually observed around the world on the last Sunday of each January with the aim of raising global awareness and knowledge about this ancient disease and calling attention to the fact that leprosy can be prevented, treated, and cured. Since 1988, the China Leprosy Association initiated China Leprosy Day on the same day.

Although leprosy has been declared “eliminated” as a public health problem at a global level by the World Health Organization (WHO) in 2005, around 200,000 new cases are reported globally each year (2). In 2011, the Chinese Ministry of Health, together with 11 other ministries, implemented the “National Strategic Plan for Eliminating Harm of Leprosy, 2011–2020 in China”, aiming to reduce both the rate of grade 2 disability (G2D) and severe adverse drug reactions (ADR) caused by multidrug therapy (3). Since then, tremendous progress has been achieved including reducing the rate of G2D to 19% and the rate of ADR to 0% (4). There were only 521 new cases registered in 2018. This progress accelerates the achievement of a leprosy-free world.

World Leprosy Day will be taking place on January 26, 2020. China’s Leprosy Day theme is “To relieve leprosy poverty & to share healthy lives”.

References
and 1970s in most areas of the country to detect most of new and historical cases in the country for treatment with monotherapy of dapsone (1). The introduction of multidrug therapy (MDT) to leprosy programs in China in the mid-1980s resulted in a significant reduction in the prevalence of the disease.

Based on the definition of WHO for elimination of leprosy as a public health problem (a prevalence of less than 1 case per 10,000 residents), China had eliminated this disease at the national level in 1981 and at the provincial level in 1992 (1). Nonetheless, this disease continued to be disproportionately detected in some areas with 1.2% of counties or cities not having reached this WHO criteria as of 2010 and resulting in a significant proportion of their patients to be disabled. To address these issues, the MOH published a national leprosy-control plan (2011–2020) to specially aim at controlling leprosy and its harms through public health investment directly allocated for leprosy control (2). The program aims to improve along three axes: the total number of leprosy patients; the percentage of counties or cities with a prevalence lower than 1/100,000; and the proportion of newly detected cases with grade 2 disabilities (G2D).

The Leprosy Management Information System in China (LEPMIS) is an updated version of the original National Leprosy Recording and Reporting System (3) that was initiated in 1990 to collect individual data on all leprosy patients reported from all counties or cities in Mainland China for establishing a national computerized database. Data from the database are analyzed regularly by the National Center for Leprosy Control and reported at annual national leprosy meetings in China and shared with the WHO. Diagnosis of leprosy was based on clinical, bacteriological, and sometimes histopathological profiles. When calculating for prevalence, patients who were not clinically cured were considered clinically active, while case detection rate was defined as the number of newly detected cases divided by population. The newly detected patients with WHO grade 2 (visible) deformities or damages were defined as “disabled” for the calculation of the disability proportion and rate of new cases.

Data from LEPMIS indicated that both the prevalence or the case detection rate of leprosy significant declined between 2010 and 2018 to reach a national prevalence of 0.178 per 100,000 and detection rate of 0.037 per 100,000 residents in 2018 (Figure 1). The number of registered cases and new cases in 2018 decreased by 58.6% and 60.6%, respectively, from that in 2010 (4–5).

The registered cases declined from 5,479 in 2011 to 2,479 in 2018 and most cases were found in Yunnan, Sichuan, Guizhou, and Guangdong. A total number of 6,602 new cases were detected from 2011 to 2018, with an average annual decline of 11.0% compared with 1,324 in 2010 (Table 1). During 2011–2018, 4,254 (64.4%) cases occurred in priority provinces of Yunnan, Guizhou, Sichuan, and Guangdong.

Among the newly detected cases in 2011–2018, male cases totaled 4,479 with a proportion of 67.8% and children under 15 years old cases totaled 141 with a proportion of 2.1%. Additionally, during this period, 11.5% of new cases were detected among people migrating from traditionally leprosy endemic areas to major cities such as Beijing, Shanghai, Guangzhou, and Shenzhen.

The number of newly detected cases with G2D was

![FIGURE 1. The prevalence rate and case detection rate of leprosy in China, 2010–2018.](image-url)
1,508 cases during 2011–2018 and the proportion of new G2D cases had remained mostly at the level around 20.0%. The proportion of G2D slowly declined to 19.0% in 2018. The rate of new leprosy cases with G2D decrease from 0.222 per 1,000,000 residents in 2010 to 0.071 per 1,000,000 residents in 2018 at the population level. Eight cases with G2D were found among children during 2011–2018, giving a proportion of G2D of 5.7% (8/141). In 2018, one case with G2D was found among children giving a proportion of G2D among children cases of 14.3% (1/7).

There were 237 counties or cities with a prevalence rate above 1/100,000 by the end of 2010. After 8 years of implementing the leprosy program in China, by the end of 2018, there were still up to 75 counties or cities where the prevalence target of more than 1/100,000 was not achieved, accounting for 2.6% of the total number of counties or cities in the country (Table 2).


<table>
<thead>
<tr>
<th>Year</th>
<th>Registered cases</th>
<th>Prevalence rate (1/100,000)</th>
<th>Total</th>
<th>Case detection rate (1/100,000)</th>
<th>Newly detected cases</th>
<th>Cases with G2D</th>
<th>Grade 2 disability rate (1/1,000,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>5,479</td>
<td>0.407</td>
<td>1,144</td>
<td>0.085</td>
<td>779</td>
<td>29</td>
<td>114</td>
</tr>
<tr>
<td>2012</td>
<td>5,071</td>
<td>0.375</td>
<td>1,206</td>
<td>0.089</td>
<td>847</td>
<td>29</td>
<td>103</td>
</tr>
<tr>
<td>2013</td>
<td>4,465</td>
<td>0.328</td>
<td>924</td>
<td>0.068</td>
<td>616</td>
<td>14</td>
<td>103</td>
</tr>
<tr>
<td>2014</td>
<td>3,961</td>
<td>0.290</td>
<td>823</td>
<td>0.060</td>
<td>560</td>
<td>14</td>
<td>109</td>
</tr>
<tr>
<td>2015</td>
<td>3,320</td>
<td>0.235</td>
<td>678</td>
<td>0.049</td>
<td>474</td>
<td>20</td>
<td>89</td>
</tr>
<tr>
<td>2016</td>
<td>2,925</td>
<td>0.212</td>
<td>672</td>
<td>0.045</td>
<td>457</td>
<td>19</td>
<td>93</td>
</tr>
<tr>
<td>2017</td>
<td>2,697</td>
<td>0.194</td>
<td>634</td>
<td>0.046</td>
<td>417</td>
<td>9</td>
<td>74</td>
</tr>
<tr>
<td>2018</td>
<td>2,479</td>
<td>0.178</td>
<td>521</td>
<td>0.037</td>
<td>329</td>
<td>7</td>
<td>74</td>
</tr>
<tr>
<td>Total</td>
<td>3,788*</td>
<td>0.276*</td>
<td>6,602</td>
<td>0.060*</td>
<td>4,479</td>
<td>141</td>
<td>756</td>
</tr>
</tbody>
</table>

Abbreviation: G2D=grade 2 disability.

*The data from 2011 to 2015 were published in Chinese Journal of Dermatology in 2017, and in this study, the data were extended to 2011–2018.

† Average data.

### TABLE 2. Main targets proposed by China’s National Program and the WHO’s Global Strategy and status of these targets by 2018 in China.

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Target of National Program by 2020*</th>
<th>Target of Global Strategy by 2020†</th>
<th>Status by the end of 2018 at national level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction in the number of registered cases from that in 2010</td>
<td>&gt;50%</td>
<td>NA</td>
<td>58.6%</td>
</tr>
<tr>
<td>Proportion of newly diagnosed cases with grade-2 disability</td>
<td>&lt;20%</td>
<td>NA</td>
<td>19.0%</td>
</tr>
<tr>
<td>Grade 2 disability rate at population</td>
<td>NA</td>
<td>&lt;1/1,000,000</td>
<td>0.071/1,000,000</td>
</tr>
<tr>
<td>Grade 2 disability rate among newly detected pediatric cases</td>
<td>NA</td>
<td>0%</td>
<td>14.3%</td>
</tr>
<tr>
<td>Proportion of counties or cities reaching the prevalence of less than 1/100,000 (N)</td>
<td>&gt;98% (2,856)</td>
<td>NA</td>
<td>97.4% (2,851)</td>
</tr>
</tbody>
</table>

Abbreviation: NA=Not applicable.

* China National Program for Eliminating Harms Due to Leprosy (2010–2020).


**DISCUSSION**

A total of 208,619 new cases of leprosy were reported globally in 2018, and 23 countries were identified by the WHO as “global priority countries” as accounting for 95.6% of the global load. China was not among these 23 priority countries, and the new case detection rate in China, approximately 0.037/100,000, was comparable to that of the United States (6) and was much lower than the global average of 2.74/100,000.

By the end of 2018, 184,212 cases were registered globally as receiving MDT, with a leprosy prevalence of 0.24/10,000. This global prevalence was over 10 times higher than the rate 0.178/100,000 reported in China in 2018. In addition, the prevalence calculated in China includes patients who were not clinically cured regardless of receiving or completing MDT, so the prevalence in China would be lower if the WHO
method of calculating prevalence, i.e. cases under MDT were calculated as registered cases, was applied.

For China to take the last steps towards becoming a leprosy-free country, innovative strategies were introduced such as symptom-driven case-detection methods combined with pay-for-performance schemes to maximize early case-finding and start earlier treatments to better prevent the development of disabilities. The symptom-driven case-detection method refers to encouraging health providers to refer any patients with symptoms suspected as leprosy for further clinical evaluation and diagnosis (7–8). The pay-for-performance scheme refers to a purchase mechanism by which subsidies were provided to compensate health providers for successful referrals for patients who were ultimately diagnosed with leprosy.

By 2018, all the main targets for 2020 have been met except for the proportion of counties or cities to reach a prevalence of less than 1/100,000 and the proportion of children cases with G2D. Globally, China might be one of the first countries to propose a leprosy elimination goal defined as a prevalence of less than 1/100,000 at the county or city level, but this goal may be difficult to achieve due to uneven disease burdens, access to and distribution of health resources, and socioeconomic status across the country.

In conclusion, China has made significant progress in the fight against leprosy, but several challenges remain. Public health systems specifically established and budgets specifically allocated for leprosy control at different levels ensured the successes of effectively controlling the disease. However, sustainability of the systems and investments is a challenge. Population migration makes case detection, treatment, and follow-up more challenging, and approximately one-tenth of newly detected cases occur annually among domestic migrants with new cases also being detected in international migrants. To address this challenge, the International Forum for Leprosy Precision Prevention and Treatment was held in China in 2018 and 2019 to congregate international representatives from Belt and Road Initiative countries.

ACKNOWLEDGEMENTS

The authors would like to appreciate all government officers, health providers, and paramedical workers who contributed to leprosy control in China. This work was supported by the China Leprosy Control Program and preparation of this paper was supported by the Discipline Construction Project of Peking Union Medical College.

* Corresponding author: Meiwen Yu, yumeiwen@163.com.

1 Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College & National Center for Leprosy Control, Chinese Center for Disease Control and Prevention, Nanjing, Jiangsu, China.

Submitted: December 31, 2019; Accepted: January 15, 2020

References